

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM545392

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	ENTITY CONVERSION		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Nalpropion Pharmaceuticals, Inc.		09/27/2019	Corporation: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Nalpropion Pharmaceuticals LLC		
<b>Street Address:</b>	10 North Park Place, Suite 201		
<b>City:</b>	Morristown		
<b>State/Country:</b>	NEW JERSEY		
<b>Postal Code:</b>	07960		
<b>Entity Type:</b>	Limited Liability Company: DELAWARE		
<b>PROPERTY NUMBERS Total: 9</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	3396021	OREXIGEN	
<b>Registration Number:</b>	3396807	OREXIGEN	
<b>Registration Number:</b>	3393576	CONTRAVE	
<b>Registration Number:</b>	4584983	WEIGHTMATE	
<b>Registration Number:</b>	5181874	CONTRAVE	
<b>Registration Number:</b>	5586961	GET CONTRAVE NOW	
<b>Registration Number:</b>	5735425	NALPROPION	
<b>Registration Number:</b>	5735551	NALPROPION PHARMACEUTICALS	
<b>Serial Number:</b>	87292362	BRAINS BEHIND WEIGHT LOSS	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	2026002261		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	(202) 600-2270		
<b>Email:</b>	aspivak@mosaiclegalgroup.com		
<b>Correspondent Name:</b>	Andrew Spivak c/o Mosaic Legal Group		
<b>Address Line 1:</b>	5185 MacArthur Boulevard, NW, Suite 350		
<b>Address Line 4:</b>	Washington, D.C. 20016-3341		
<b>NAME OF SUBMITTER:</b>	Andrew N. Spivak		

OP \$240.00 3396021


<b>SIGNATURE:</b>	/Andrew N. Spivak/
<b>DATE SIGNED:</b>	10/16/2019
<b>Total Attachments: 6</b> source=Nalpropion Pharmaceuticals Inc. to LLC - Delaware Conversion Document#page1.tif source=Nalpropion Pharmaceuticals Inc. to LLC - Delaware Conversion Document#page2.tif source=Nalpropion Pharmaceuticals Inc. to LLC - Delaware Conversion Document#page3.tif source=Nalpropion Pharmaceuticals Inc. to LLC - Delaware Conversion Document#page4.tif source=Nalpropion Pharmaceuticals Inc. to LLC - Delaware Conversion Document#page5.tif source=Nalpropion Pharmaceuticals Inc. to LLC - Delaware Conversion Document#page6.tif	

# Delaware

The First State

Page 1

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THAT THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF CONVERSION OF A DELAWARE CORPORATION UNDER THE NAME OF "NALPROPION PHARMACEUTICALS, INC." TO A DELAWARE LIMITED LIABILITY COMPANY, CHANGING ITS NAME FROM "NALPROPION PHARMACEUTICALS, INC." TO "NALPROPION PHARMACEUTICALS LLC", FILED IN THIS OFFICE ON THE TWENTY-SEVENTH DAY OF SEPTEMBER, A.D. 2019, AT 1:50 O'CLOCK P.M.



6549244 8100V  
SN# 20197269860

You may verify this certificate online at [corp.delaware.gov/authver.shtml](http://corp.delaware.gov/authver.shtml)

Handwritten signature of Jeffrey W. Bullock, Secretary of State, over a horizontal line.

Jeffrey W. Bullock, Secretary of State

Authentication: 203683994  
Date: 09-27-19

**TRADEMARK**  
**REEL: 006772 FRAME: 0526**

**CERTIFICATE OF CONVERSION  
FROM A CORPORATION  
TO A LIMITED LIABILITY COMPANY**

Pursuant to Section 18-214 of the Delaware Limited Liability Company Act and  
Section 266 of the General Corporation Law of the State of Delaware

1. The name of the Corporation immediately prior to the filing of this Certificate of Conversion is *Nalpropion Pharmaceuticals, Inc.*
2. The Corporation was originally incorporated on April 17, 2018, under the laws of the State of Delaware. The jurisdiction of the Corporation immediately prior to the filing of this Certificate of Conversion is the State of Delaware.
3. The name of the Limited Liability Company into which the Corporation shall be converted, as set forth in its Certificate of Formation, is *Nalpropion Pharmaceuticals LLC.*

*[Signature page follows]*

BE WITNESS WHEREOF, the undersigned has executed this  
Certificate of Conversion as of this 27 day of September, 2019.

NALPROPION PHARMACEUTICALS, INC.

By:   
Name: Aaron Baratta  
Title: Vice President of Sales


*[Signature page to Certificate of Conversion]*

# Delaware

The First State

Page 1

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE DO HEREBY CERTIFY THAT THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF FORMATION OF "NALPROPION PHARMACEUTICALS LLC" FILED IN THIS OFFICE ON THE TWENTY-SEVENTH DAY OF SEPTEMBER, A.D. 2019, AT 1:50 O'CLOCK P.M.



6848244 8100V  
SR# 20197289860

You may verify this certificate online at [corp.delaware.gov/authver.shtml](http://corp.delaware.gov/authver.shtml)

A handwritten signature in black ink, appearing to read "JWB", written over a horizontal line. Below the line, the text "Jeffrey W. Bullock, Secretary of State" is printed in a small font.

Authentication: 203683994

Date: 09-27-19

**TRADEMARK**  
**REEL: 006772 FRAME: 0529**

State of Delaware  
Secretary of State  
Division of Corporations  
Delivered 01:50 PM 09/27/2019  
FILED 01:50 PM 09/27/2019  
SR 20197289660 - File Number 0848244


**LIMITED LIABILITY COMPANY  
CERTIFICATE OF FORMATION**

1. The name of the limited liability company is Nalprocion  
Pharmaceuticals LLC.

2. The address of its registered office in the State of Delaware is 251  
Little Falls Drive, Wilmington, New Castle County, Delaware 19808. The name of  
its registered agent at such address is Corporation Service Company.

*[Signature page follows]*

IN WITNESS WHEREOF, the undersigned has executed this  
Certificate of Formation as of the 27<sup>th</sup> day of September, 2019.

By:   
Name: Aaron Barata  
Title: Authorized Person

*[Signature page to Certificate of Formation]*